US20030100610A1 - Use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events - Google Patents

Use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events Download PDF

Info

Publication number
US20030100610A1
US20030100610A1 US10/281,208 US28120802A US2003100610A1 US 20030100610 A1 US20030100610 A1 US 20030100610A1 US 28120802 A US28120802 A US 28120802A US 2003100610 A1 US2003100610 A1 US 2003100610A1
Authority
US
United States
Prior art keywords
subjects
major cardiovascular
epa
cardiovascular event
dha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/281,208
Inventor
Hajime Shibuya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pro Aparts Investimentos e Consultoria Ltda
Original Assignee
Quatex NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11448595&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20030100610(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Quatex NV filed Critical Quatex NV
Publication of US20030100610A1 publication Critical patent/US20030100610A1/en
Assigned to QUATEX N.V. reassignment QUATEX N.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HAJIME, SHIBUYA
Priority to US10/778,182 priority Critical patent/US7553870B2/en
Assigned to QUATEX N.V. reassignment QUATEX N.V. RECORD TO CORRECT ASSIGNOR'S NAME ON AN ASSIGNMENT PREVIOUSLY RECORDED AT REEL 014193 FRAME 0725 Assignors: SHIBUYA, HAJIME
Assigned to PRO APARTS INVESTIMENTOS E CONSULTORIA LDA. reassignment PRO APARTS INVESTIMENTOS E CONSULTORIA LDA. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: QUATEX N.V.
Priority to US11/984,485 priority patent/US7619002B2/en
Priority to US12/568,997 priority patent/US8648061B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the invention relates to the use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events.
  • the invention concerns the use of polyunsaturated fatty acids of the ⁇ -3 series such as eicosapentaenoic acid (EPA, C 20:5 ⁇ -3), docosahexaenoic acid (DHA, C 22:6 ⁇ -3), or their pharmaceutically acceptable derivatives, either alone or mixed together, for the primary prevention of major cardiovascular events.
  • polyunsaturated fatty acids of the ⁇ -3 series such as eicosapentaenoic acid (EPA, C 20:5 ⁇ -3), docosahexaenoic acid (DHA, C 22:6 ⁇ -3), or their pharmaceutically acceptable derivatives, either alone or mixed together, for the primary prevention of major cardiovascular events.
  • U.S. Pat. No. 5,753,703 describes the use of L-carnitine or its derivatives in association with polyunsaturated fatty acids of the ⁇ -3 series or their esters, in particular EPA and DHA, for the prevention and treatment of cardiovascular disorders, vascular pathologies, diabetic peripheral neuropathies, and atherosclerotic, thromboembolytic and tissue disorders.
  • EP-B-0409903 describes a process for preparing high concentration mixtures of EPA and DHA and/or their esters useful for treating hyperlipemia and related pathologies, thrombosis, cardiac infarct, platelet aggregation, as anticoagulants in the prevention of atherosclerosis, for the treatment of cerebral infarct, of lesions and occlusions caused by vasomotor spasms, of diabetes and its complications, of chronic and acute inflammations, of autoimmune symptoms, in the prevention of side effects caused by non-steroid anti-inflammatories at the gastrointestinal level and in tumour prevention.
  • CN 1082909 describes compositions based on ethyl esters of EPA and DHA and other polyunsaturated fatty acids of the ⁇ -3 series in association with soya phospholipids, oenothera odorata and ginkgetin, as antithrombotic and antidementia agents for treating for example dementia and infarct of the myocardium.
  • U.S. Pat. No. 5,760,081 describes a method for preventing imminent fibrillation of the myocardial ventricle by intravenous infusion of a composition containing EPA, where the subject at risk of imminent fibrillation has already often been the protagonist of an episode of infarct of the myocardium and where the infusion is effected within 3 hours of the infarct episode, possibly using intracardiac injection.
  • WO 00/48592 describes the use of a mixture of EPA and DHA ethylesters in quantities greater than 25 wt. % for preventing death, in particular “sudden death” in patients who have already suffered an infarct of the myocardium. This therefore represents the use of said mixture in so-called secondary death prevention, i.e. in subjects who have already suffered infarct.
  • the invention relates to the use of polyunsaturated fatty acids of the ⁇ -3 series for the preparation of a drug useful in the primary prevention of a major cardiovascular event in subjects who have not undergone previous infarct episodes, wherein the fatty acids comprise eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA) and/or at least one pharmaceutically acceptable derivative thereof, in quantities greater than or equal to 25 wt % on the total fatty acid weight.
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • polyunsaturated fatty acids of the ⁇ -3 series means those long-chain polyunsaturated fatty acids, generally C 16 -C 24 , containing fish oils, in particular those having a C 20 -C 22 chain, which are predominant in purification processes.
  • major cardiovascular event means in particular those events which involve reversible or irreversible cardiovascular damage, such as infarct of the myocardium and of individual coronary branches, death from cardiac causes, sudden death, etc., besides to infarct, broadly speaking, ictus etc., and those conditions prodromal to such major events, such as myocardial fibrillation, atrial and/or ventricular fibrillation, etc.
  • Said major cardiovascular events are usually induced by various cardiocirculatory and cardiorespiratory pathologies such as coronary ischemic illness not displayed by previous infarct episodes, and by serious hypoxic/anoxic states caused by a sudden lack of oxygen (for example during anesthesia, surgery, etc.), possibly in the presence of conditions which contemplate an increase in the oxygen requirement (accentuated physical stress, drug abuse, acute hypertensive crises, etc.) and analogous acute and chronic pathologies due to cardiac defects of electrical and/or mechanical type.
  • various cardiocirculatory and cardiorespiratory pathologies such as coronary ischemic illness not displayed by previous infarct episodes, and by serious hypoxic/anoxic states caused by a sudden lack of oxygen (for example during anesthesia, surgery, etc.), possibly in the presence of conditions which contemplate an increase in the oxygen requirement (accentuated physical stress, drug abuse, acute hypertensive crises, etc.) and analogous acute and chronic pathologies due to cardiac defects of electrical and/or mechanical type.
  • the subjects affected by pathologies of the cardiocirculatory and cardiorespiratory system are representative of subjects definable at various levels as cardiopaths, by being affected, for example, by coronary ischemia detectable by coronarography, scintigraphy of the myocardium, electrocardiogram (ECG) under stress, etc., against which interventions of revascularization (angioplasty) or other possible pharmacological or invasive treatments have been proposed, and of subjects affected by electrical hyperexcitability of the myocardium cells, disorder of the diffusion of electrical excitement or of electrical conduction (arrhythmia, fibrillation, etc.) or by other defects of mechanical type (cardiac insufficiency, decompensation), possibly aggravated by concomitant pathologies such as diabetes.
  • polyunsaturated fatty acids of the w-3 series according to the invention is particularly indicated if the occurrence of a major event is predicted, such as an infarct, in particular of the myocardium, death from a cardiological cause, or sudden death, and where such an occurrence takes place in cardiopathic subjects affected, for example, by coronary ischemia, arrhythmia, atrial and/or ventricular fibrillation, electrical hyperexcitability of the myocardium cells, disorder of the diffusion of electrical excitement or of electrical conduction of the myocardium, or cardiac disorders of mechanical type, for example cardiac insufficiency or cardiac decompensation, possibly affected by diabetic pathology concomitant with the cardiopathy.
  • a major event such as an infarct, in particular of the myocardium, death from a cardiological cause, or sudden death, and where such an occurrence takes place in cardiopathic subjects affected, for example, by coronary ischemia, arrhythmia, atrial and/or ventricular fibrillation, electrical hyperex
  • the content of EPA and/or DHA and/or of the at least one derivative thereof is between 50% and 100%, in particular between 75% and 95%, and more preferably about 85% by weight on the total fatty acid weight.
  • the preferred EPA and/or DHA derivatives are selected from the corresponding C 1 -C 3 alkyl esters and/or from their salts with pharmaceutically acceptable bases such as sodium hydroxide, lysine, arginine or aminoalcohols such as choline.
  • pharmaceutically acceptable bases such as sodium hydroxide, lysine, arginine or aminoalcohols such as choline.
  • the ethylesters of EPA and DHA, in particular mixed together in any concentration and percentage, are the most preferred.
  • the drug is administered preferably orally, in particular in the form of soft gelatin capsules.
  • the unit dose generally comprises 100-1000 mg of polyunsaturated fatty acids of the ⁇ -3 series, preferably 500-1000 mg or 300-500 mg, the total dose being usually around 0.1-3.0 g per day or per alternate day, according to the case concerned, and preferably 0.3-2.0 g per day and in particular 1.0 g per day.
  • the effective dose of the drug suitable for the use of the invention is 1.0-60.0 mg/kg of body weight/day.
  • formulation for oral administration are also suitable for the purposes of the invention; for example hard capsules or tablets, in which the polyunsaturated fatty acids are adsorbed on solid supports. It is also possible to use emulsions, granulates in dispersing excipients, syrups, droplets, etc., and other forms of administration able to ensure systemic absorption of the drug, such as sterile solutions or emulsions and the like, suitable for parenteral use and the like, as evaluated by the expert of the art, on the basis of the severity of the pathology.
  • compositions illustrated in the European Pharmacopea 2000 containing quantities greater than or equal to 80 wt % of mixtures of EPA and DHA ethylesters and a total of ⁇ -3 polyunsaturated fatty acid ethylesters greater than or equal to 90 wt % are also suitable for the purposes of the present invention.
  • compositions and the drugs suitable for the use of the invention can be prepared by methods known to the expert of the art, such as those described in U.S. Pat. No. 5,130,061, WO 89/11521, IT 1235879, JP 02/25447, which are incorporated into the present description with regard to the method of preparation.
  • the drug suitable for use according to the present invention can also comprise other active principles and/or drugs, in association, possessing activity complementary to or synergic with that of the drug suitable for use according to the invention, and also at least one pharmaceutically acceptable vehicle and/or one diluent and/or one surfactant and/or one thickener and/or one binder and/or one lubricant and/or one aromatizer and/or one colorant and/or one stabilizer and the like, which can easily be selected by the expert of the art.
  • stabilizers antioxidants such as vitamin E (tocopherol), ascorbyl palmitate, ascorbic acid, hydroxytoluene and the like, which can be easily selected by the expert of the art, are particularly preferred.
  • the invention relates to a method for the primary prevention of a major cardiovascular event in subjects who have not undergone previous infarct episodes, comprising the administration of an effective dose of a drug comprising polyunsaturated fatty acids of the ⁇ -3 series as hereinbefore described.
  • the method of the invention is indicated whenever the occurrence of a major cardiac event is predicted such as an infarct, in particular of the myocardium, death from a cardiological cause or sudden death.
  • compositions illustrated in the following table were prepared by the methods described in U.S. Pat. No. 5,130,061 (compositions A, C, D, F), IT 1235879 (composition B), JP 02/25447 (composition E) and WO 89/11521 (compositions G-I).
  • compositions illustrated in the following table were prepared by methods known in the art.
  • compositions of the invention were evaluated on the basis of tests carried out on small laboratory animals (mouse, guinea pig, rat); this experimental model was chosen because of the ability to make rapid and highly reproducible verifications and to use a sufficiently large number of animals, such as to enable a statistically accurate evaluation of the results to be made without exposing the patient to risk, with evident ethical implications.
  • the experimental sudden death model was obtained by cardiac arrest induced by intravenous (i.v.) administration of a cardiotoxic agent (ouabain).
  • ouabain a cardiotoxic agent
  • various doses of ouabain were administered to non-anesthetized guinea pigs of both sexes of weight 300-380 g, in order to determine the minimum lethal dose for 100% of the animals within 15 minutes from i.v. injection (240 mg/kg, intravenously administered over 3 minutes).
  • composition A 3 groups of 15 male mice, initial weight 25-32 g, were treated orally for 15 days with physiological solution (control group) and with 50 or 100 mg/kg of a composition containing 85% of EPA and DHA ethylesters (Ex. 1, composition A).
  • T t 1 (sec) t 2 (sec) t 3 (sec) S C 123 ⁇ 12 174 ⁇ 7 214 ⁇ 32 00/15 (15/15) (15/15) (15/15) 50 mg/kg 168 ⁇ 8 235 ⁇ 16 350 ⁇ 26 09/15 (08/15) (06/15) (06/15) 100 mg/kg 195 ⁇ 15 284 ⁇ 18 378 ⁇ 35 12/15 (05/15) (03/15) (03/15)
  • composition C 4 groups of 10 male mice, initial weight 26-32 g, were treated orally for 5 days with physiological solution (control group) and with 10, 30 and 60 mg/kg of a composition containing 80% of EPA and DHA ethylesters (Ex. 1, composition C).

Abstract

The use of polyunsaturated fatty acids of the ω-3 series such as eicosapentaenoic acid (EPA, C20:5 ω-3), docosahexaenoic acid (DHA, C22:6 ω-3), or their pharmaceutically acceptable derivatives is described for the primary prevention of major cardiovascular events in subjects who have not undergone previous infarct episodes.

Description

  • The invention relates to the use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events. [0001]
  • In particular, the invention concerns the use of polyunsaturated fatty acids of the ω-3 series such as eicosapentaenoic acid (EPA, C[0002] 20:5 ω-3), docosahexaenoic acid (DHA, C22:6 ω-3), or their pharmaceutically acceptable derivatives, either alone or mixed together, for the primary prevention of major cardiovascular events.
  • The beneficial effects of polyunsaturated fatty acids of the ω-3 series on multiple risk factors for cardiovascular illnesses are well known; for example the patents IT 1235879, U.S. Pat. No. 5,502,077, U.S. Pat. No. 5,656,667 and U.S. Pat. No. 5,698,594 refer respectively to hypertriglyceridemia, defects of the cholesterol level and hypertension. However, each of the cited documents deal with the treatment of risk factors, not with real and proclaimed illnesses. [0003]
  • U.S. Pat. No. 5,753,703 describes the use of L-carnitine or its derivatives in association with polyunsaturated fatty acids of the ω-3 series or their esters, in particular EPA and DHA, for the prevention and treatment of cardiovascular disorders, vascular pathologies, diabetic peripheral neuropathies, and atherosclerotic, thromboembolytic and tissue disorders. [0004]
  • EP-B-0409903 describes a process for preparing high concentration mixtures of EPA and DHA and/or their esters useful for treating hyperlipemia and related pathologies, thrombosis, cardiac infarct, platelet aggregation, as anticoagulants in the prevention of atherosclerosis, for the treatment of cerebral infarct, of lesions and occlusions caused by vasomotor spasms, of diabetes and its complications, of chronic and acute inflammations, of autoimmune symptoms, in the prevention of side effects caused by non-steroid anti-inflammatories at the gastrointestinal level and in tumour prevention. [0005]
  • CN 1082909 describes compositions based on ethyl esters of EPA and DHA and other polyunsaturated fatty acids of the ω-3 series in association with soya phospholipids, oenothera odorata and ginkgetin, as antithrombotic and antidementia agents for treating for example dementia and infarct of the myocardium. [0006]
  • U.S. Pat. No. 5,760,081 describes a method for preventing imminent fibrillation of the myocardial ventricle by intravenous infusion of a composition containing EPA, where the subject at risk of imminent fibrillation has already often been the protagonist of an episode of infarct of the myocardium and where the infusion is effected within 3 hours of the infarct episode, possibly using intracardiac injection. These are always situations of extreme emergency and of parenteral intervention, for the specific treatment of ventricular fibrillation. [0007]
  • Swann et al., Clinical Drug Investigation 15 (6), 473, 1998 have also shown that the administration of EPA and DHA ethylesters, at a dose of 4 g per day, leads to a decrease in triglycerides and total apolipoprotein C III and to an increase in antithrombin III, in subjects-with abnormal plasmatic lipoprotein symptoms and have undergone an infarct of the myocardium, they having consequently suggested that an administration of these compositions can result in an improvement in the lipoprotein level and hence a decrease in the relative risk factors. [0008]
  • WO 00/48592 describes the use of a mixture of EPA and DHA ethylesters in quantities greater than 25 wt. % for preventing death, in particular “sudden death” in patients who have already suffered an infarct of the myocardium. This therefore represents the use of said mixture in so-called secondary death prevention, i.e. in subjects who have already suffered infarct. [0009]
  • The prevention of cardiovascular damage by means of fatty acid mixtures described in the state of the art is therefore focused on “secondary” prevention of cardiovascular damage. i.e. aimed at protecting a subject who has already suffered an infarct, whereas “primary” prevention of major cardiovascular events, i.e. prevention in subjects who, while affected by various pathologies of the cardiocirculatory and/or cardiorespiratory systems, have not yet suffered an infarct episode, constitutes a technical problem which is still felt in this sector. [0010]
  • According to a first aspect the invention relates to the use of polyunsaturated fatty acids of the ω-3 series for the preparation of a drug useful in the primary prevention of a major cardiovascular event in subjects who have not undergone previous infarct episodes, wherein the fatty acids comprise eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA) and/or at least one pharmaceutically acceptable derivative thereof, in quantities greater than or equal to 25 wt % on the total fatty acid weight. [0011]
  • In the present description, the expression “polyunsaturated fatty acids of the ω-3 series” means those long-chain polyunsaturated fatty acids, generally C[0012] 16-C24, containing fish oils, in particular those having a C20-C22 chain, which are predominant in purification processes.
  • The expression “major cardiovascular event” means in particular those events which involve reversible or irreversible cardiovascular damage, such as infarct of the myocardium and of individual coronary branches, death from cardiac causes, sudden death, etc., besides to infarct, broadly speaking, ictus etc., and those conditions prodromal to such major events, such as myocardial fibrillation, atrial and/or ventricular fibrillation, etc. Said major cardiovascular events are usually induced by various cardiocirculatory and cardiorespiratory pathologies such as coronary ischemic illness not displayed by previous infarct episodes, and by serious hypoxic/anoxic states caused by a sudden lack of oxygen (for example during anesthesia, surgery, etc.), possibly in the presence of conditions which contemplate an increase in the oxygen requirement (accentuated physical stress, drug abuse, acute hypertensive crises, etc.) and analogous acute and chronic pathologies due to cardiac defects of electrical and/or mechanical type. [0013]
  • The subjects affected by pathologies of the cardiocirculatory and cardiorespiratory system, hence not simply at prospective risk due to hypertriglyceridemia, hypertension or other, are representative of subjects definable at various levels as cardiopaths, by being affected, for example, by coronary ischemia detectable by coronarography, scintigraphy of the myocardium, electrocardiogram (ECG) under stress, etc., against which interventions of revascularization (angioplasty) or other possible pharmacological or invasive treatments have been proposed, and of subjects affected by electrical hyperexcitability of the myocardium cells, disorder of the diffusion of electrical excitement or of electrical conduction (arrhythmia, fibrillation, etc.) or by other defects of mechanical type (cardiac insufficiency, decompensation), possibly aggravated by concomitant pathologies such as diabetes. [0014]
  • The use of polyunsaturated fatty acids of the w-3 series according to the invention is particularly indicated if the occurrence of a major event is predicted, such as an infarct, in particular of the myocardium, death from a cardiological cause, or sudden death, and where such an occurrence takes place in cardiopathic subjects affected, for example, by coronary ischemia, arrhythmia, atrial and/or ventricular fibrillation, electrical hyperexcitability of the myocardium cells, disorder of the diffusion of electrical excitement or of electrical conduction of the myocardium, or cardiac disorders of mechanical type, for example cardiac insufficiency or cardiac decompensation, possibly affected by diabetic pathology concomitant with the cardiopathy. [0015]
  • Preferably, the content of EPA and/or DHA and/or of the at least one derivative thereof is between 50% and 100%, in particular between 75% and 95%, and more preferably about 85% by weight on the total fatty acid weight. The preferred EPA and/or DHA derivatives are selected from the corresponding C[0016] 1-C3 alkyl esters and/or from their salts with pharmaceutically acceptable bases such as sodium hydroxide, lysine, arginine or aminoalcohols such as choline. The ethylesters of EPA and DHA, in particular mixed together in any concentration and percentage, are the most preferred.
  • The drug is administered preferably orally, in particular in the form of soft gelatin capsules. For oral use, the unit dose generally comprises 100-1000 mg of polyunsaturated fatty acids of the ω-3 series, preferably 500-1000 mg or 300-500 mg, the total dose being usually around 0.1-3.0 g per day or per alternate day, according to the case concerned, and preferably 0.3-2.0 g per day and in particular 1.0 g per day. The effective dose of the drug suitable for the use of the invention is 1.0-60.0 mg/kg of body weight/day. [0017]
  • Other types of formulation for oral administration are also suitable for the purposes of the invention; for example hard capsules or tablets, in which the polyunsaturated fatty acids are adsorbed on solid supports. It is also possible to use emulsions, granulates in dispersing excipients, syrups, droplets, etc., and other forms of administration able to ensure systemic absorption of the drug, such as sterile solutions or emulsions and the like, suitable for parenteral use and the like, as evaluated by the expert of the art, on the basis of the severity of the pathology. [0018]
  • Those compositions illustrated in the European Pharmacopea 2000 (EuPh. 2000), containing quantities greater than or equal to 80 wt % of mixtures of EPA and DHA ethylesters and a total of ω-3 polyunsaturated fatty acid ethylesters greater than or equal to 90 wt % are also suitable for the purposes of the present invention. [0019]
  • The aforestated compositions and the drugs suitable for the use of the invention can be prepared by methods known to the expert of the art, such as those described in U.S. Pat. No. 5,130,061, WO 89/11521, IT 1235879, JP 02/25447, which are incorporated into the present description with regard to the method of preparation. [0020]
  • The drug suitable for use according to the present invention can also comprise other active principles and/or drugs, in association, possessing activity complementary to or synergic with that of the drug suitable for use according to the invention, and also at least one pharmaceutically acceptable vehicle and/or one diluent and/or one surfactant and/or one thickener and/or one binder and/or one lubricant and/or one aromatizer and/or one colorant and/or one stabilizer and the like, which can easily be selected by the expert of the art. Of the stabilizers, antioxidants such as vitamin E (tocopherol), ascorbyl palmitate, ascorbic acid, hydroxytoluene and the like, which can be easily selected by the expert of the art, are particularly preferred. [0021]
  • According to another aspect, the invention relates to a method for the primary prevention of a major cardiovascular event in subjects who have not undergone previous infarct episodes, comprising the administration of an effective dose of a drug comprising polyunsaturated fatty acids of the ω-3 series as hereinbefore described. In particular, the method of the invention is indicated whenever the occurrence of a major cardiac event is predicted such as an infarct, in particular of the myocardium, death from a cardiological cause or sudden death.[0022]
  • The following examples illustrate the invention but without limiting it. [0023]
  • The compositions illustrated in the following table were prepared by the methods described in U.S. Pat. No. 5,130,061 (compositions A, C, D, F), IT 1235879 (composition B), JP 02/25447 (composition E) and WO 89/11521 (compositions G-I). [0024]
  • All the quantities indicated in the following table express percentages by weight on the total weight of polyunsaturated fatty acids of the ω-3 series. [0025]
    A1 B1 C1 D1 E1 F1 G1 H2 I3
    EPA >40 >44 >40 >25 >80 >20 <15 >40 >40
    DHA >34 >30 >34 >20 <10 >25 >80 >30 >30
    EPA + DHA >85 >80 >80 >50 >80 >50 >85 >80 >80
    esters4 >3
    tot.esters5 >90
    α-tocopherol 0.03 0.03 0.1 0.3 0.1 0.3 0.03 0.1 0.1
  • EXAMPLE 2
  • The compositions illustrated in the following table, relative to soft gelatin capsules containing 1 g of polyunsaturated fatty acid ethyl esters, were prepared by methods known in the art. [0026]
    A (mg) B (mg) C (mg)
    EPA1 525 >400
    DHA1 315 >340
    EPA + DHA 850 >800
    Total ω-31 >900
    d-α-tocopherol 4 I.U. 4 I.U.
    d,I-α-tocopherol 0.3
    gelatin 246 246
    gelatin succinate 233
    glycerol 118 67 118
    OFR 2.27 2.27
    OFG 1.27 1.27
    SOB 1.09
    SPOB 0.54
  • Pharmacological Activity [0027]
  • The pharmacological activity of the compositions of the invention was evaluated on the basis of tests carried out on small laboratory animals (mouse, guinea pig, rat); this experimental model was chosen because of the ability to make rapid and highly reproducible verifications and to use a sufficiently large number of animals, such as to enable a statistically accurate evaluation of the results to be made without exposing the patient to risk, with evident ethical implications. [0028]
  • During the course of these tests, groups of animals were pretreated repeatedly with the formulations of Examples 1 and 2 and then, in comparison with untreated groups, were subjected to the action of cardiotoxic or respiration-depressive substances, then visually measuring protection against death, or—by means of elettrocardiographic recording—measuring the delay in the start of initial cardiac arrhythmia or of ventricular tachycardia and above all the delay in or the prevention of animal death due to sudden cardiac and/or respiratory arrest. [0029]
  • Using an analogous experimental model, cardiological pathology, coronary ischemia and a state of infarct were induced by coronary ligature instead of by cardiotoxic agents. [0030]
  • Test 1 [0031]
  • The experimental sudden death model was obtained by cardiac arrest induced by intravenous (i.v.) administration of a cardiotoxic agent (ouabain). In preliminary tests, various doses of ouabain were administered to non-anesthetized guinea pigs of both sexes of weight 300-380 g, in order to determine the minimum lethal dose for 100% of the animals within 15 minutes from i.v. injection (240 mg/kg, intravenously administered over 3 minutes). [0032]
  • Two groups of 20 guinea pigs were then treated with 50 and 100 mg/kg of a composition containing 85% of EPA and DHA ethylesters (Ex. 1, composition A) for 10 days. After 2 hours from the last administration the two groups of guinea pigs and a further untreated group, used as control, were treated with 240 mg/kg i.v. of ouabain, recording mortality within the subsequent 15 minutes. [0033]
  • Results expressed as survivors after 15 minutes: [0034]
    Controls 00/20
    50 mg/kg 11/20
    100 mg/kg 16/20
  • Test 2 [0035]
  • 3 groups of 15 male mice, initial weight 25-32 g, were treated orally for 15 days with physiological solution (control group) and with 50 or 100 mg/kg of a composition containing 85% of EPA and DHA ethylesters (Ex. 1, composition A). [0036]
  • 60 minutes after the end of the last treatment, the animals of all the groups were treated with sodium pentabarbital i.p. (50 mg/kg) and then with aconitine i.v. (0.25 mg/kg). The times of appearance of cardiac arrhythmia (deviation >5 seconds from the normal sinus rhythm), of ventricular fibrillation and of cardiac arrest were determined by electrocardiograph recording. Results expressed as mean±standard deviation (seconds) on the positive animals. [0037]
    T t1 (sec) t2 (sec) t3 (sec) S
    C 123 ± 12 174 ± 7 214 ± 32 00/15
    (15/15) (15/15) (15/15)
    50 mg/kg 168 ± 8 235 ± 16 350 ± 26 09/15
    (08/15) (06/15) (06/15)
    100 mg/kg 195 ± 15 284 ± 18 378 ± 35 12/15
    (05/15) (03/15) (03/15)
  • Test 3 [0038]
  • 2 groups of 20 male rats, initial weight 310-350 g, were treated orally for 15 days with physiological solution (control group) and with 100 mg/kg of a composition containing >80% of EPA and DHA ethylesters (Ex. 1, composition B). The rats of the 2 groups were then anesthetized with sodium pentobarbital i.p. (50 mg/kg), then subjected to ligature of the left anterior descending coronary artery, which allows blood flow to the left ventricle, so inducing an acute ischemic state of the myocardium. During the subsequent 15 minutes the duration of ventricular fibrillation was recorded by ECG, this either resolving itself spontaneously or concluding with sudden death. [0039]
  • Results [0040]
    T F (sec) Mortality S (%)
    C 190 ± 24 16/20 20
    (18/20)
    100 mg/kg 55 ± 5 01/20 95
    (04/20)
  • Test 4 [0041]
  • The experimental model implemented for sudden death by respiratory arrest involves its inducement by chloroform inhalation. [0042]
  • 4 groups of 10 male mice, initial weight 26-32 g, were treated orally for 5 days with physiological solution (control group) and with 10, 30 and 60 mg/kg of a composition containing 80% of EPA and DHA ethylesters (Ex. 1, composition C). [0043]
  • 60 minutes after the end of the last treatment, the animals were exposed to chloroform until respiratory arrest had occurred. The animals were then checked for tachyarrhythmia of the myocardium induced by the hypoxic state, this either resolving itself spontaneously within the next 15 minutes or concluding with death of the animal. [0044]
  • Results [0045]
    Protection from
    Treatment tachyarrhythmia Survivals
    Control 00/10 03/10
    10 mg/kg 04/10 06/10
    30 mg/kg 07/10 08/10
    60 mg/kg 09/10 10/10
  • Test 5 [0046]
  • 2 groups of 20 male rats were treated as on Test 3, with physiological solution and with the same EPA and DHA composition (Example 1, composition B). [0047]
  • Ligature of the circumflex coronary artery was then effected, with consequent reduction in the contractile capacity of the myocardium and of the ejection fraction. The mortality of 18/20 animals of the control group fell to 4/20 of the treated group, during the course of the subsequent 60 minutes. [0048]
  • The clinical results of the tests demonstrate the pharmacological activity of the polyunsaturated fatty acids of the ω-3 series in the primary prevention of major cardiovascular events in subjects who have not undergone previous infarct episodes. [0049]

Claims (27)

1. Use of polyunsaturated fatty acids of the ω-3 series for the preparation of a drug useful in the primary prevention of a major cardiovascular event in subjects who have not undergone previous infarct episodes, wherein the fatty acids comprise eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA) and/or at least one pharmaceutically acceptable derivative thereof, in quantities greater than or equal to 25 wt % on the total fatty acid weight.
2. Use as claimed in claim 1, wherein the major cardiovascular event is infarct.
3. Use as claimed in claim 1, wherein the major cardiovascular event is infarct of the myocardium.
4. Use as claimed in claim 1, wherein the major cardiovascular event is death from a cardiological cause.
5. Use as claimed in claim 1, wherein the major cardiovascular event is sudden death.
6. Use as claimed in any one of the preceding claims, wherein the subjects are cardiopathic.
7. Use as claimed in any one of the preceding claims, wherein the subjects are affected by coronary ischemia.
8. Use as claimed in any one of the preceding claims, wherein the subjects are affected by arrhythmia, fibrillation, electrical hyperexcitability of the myocardium cells, disorder of diffusion of the electrical excitement and of electrical conduction of the myocardium.
9. Use as claimed in any one of the preceding claims, wherein the subjects are affected by cardiac disorders of mechanical type.
10. Use as claimed in any one of the preceding claims, wherein the subjects are affected by cardiac insufficiency.
11. Use as claimed in any one of the preceding claims, wherein the subjects are affected by cardiac decompensation.
12. Use as claimed in any one of claims from 6 to 11, wherein the subjects are affected by diabetic pathology concomitant with cardiopathy.
13. Use as claimed in any one of the preceding claims, wherein the content of EPA and/or DHA and/or of the at least one derivative thereof is between 50% and 100% by weight on the total fatty acid weight.
14. Use as claimed in any one of the preceding claims, wherein the content of EPA and/or DHA and/or of the at least one derivative thereof is between 75% and 95% by weight on the total fatty acid weight.
15. Use as claimed in any one of the preceding claims, wherein the content of EPA and/or DHA and/or of the at least one derivative thereof is equal to about 85% by weight on the total fatty acid weight.
16. Use as claimed in any one of the preceding claims, wherein the at least one derivative of EPA and/or DHA is selected from the corresponding C1-C3 alkyl esters and/or acids and/or salts with pharmaceutically acceptable bases.
17. Use as claimed in any one of the preceding claims, wherein the drug comprises EPA ethylester and/or DHA ethylester.
18. Use as claimed in any one of the preceding claims, wherein the drug is administered orally.
19. Use as claimed in any one of the preceding claims, wherein the drug is in the form of soft gelatin capsules.
20. Use as claimed in any one of the preceding claims, wherein the drug is administered at a dose of 0.1-3.0 g per day.
21. Use as claimed in any one of the preceding claims, wherein the drug is administered at a dose of 0.3-2.0 g per day.
22. Use as claimed in any one of the preceding claims, wherein the drug is administered at a dose of 1.0 g per day.
23. A method for the primary prevention of a major cardiovascular event in subjects who have not undergone previous infarct episodes, comprising the administration of an effective dose of a drug claimed in any one of the preceding claims.
24. A method as claimed in the preceding claim, wherein the major cardiovascular event is infarct.
25. A method as claimed in claim 23, wherein the major cardiovascular event is infarct of the myocardium.
26. A method as claimed in claim 23, wherein the major cardiovascular event is death from a cardiological cause.
27. A method as claimed in claim 23, wherein the major cardiovascular event is sudden death.
US10/281,208 2001-11-12 2002-10-28 Use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events Abandoned US20030100610A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/778,182 US7553870B2 (en) 2001-11-12 2004-02-17 Use of polyunsaturated fatty acid for the primary prevention of major cardiovascular events
US11/984,485 US7619002B2 (en) 2001-11-12 2007-11-19 Use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events
US12/568,997 US8648061B2 (en) 2001-11-12 2009-09-29 Use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2001A002384 2001-11-12
IT2001MI002384A ITMI20012384A1 (en) 2001-11-12 2001-11-12 USE OF POLYUNSATURATED FATTY ACIDS FOR THE PRIMARY PREVENTION OF MAJOR CARDIOVASCULAR EVENTS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/778,182 Division US7553870B2 (en) 2001-11-12 2004-02-17 Use of polyunsaturated fatty acid for the primary prevention of major cardiovascular events

Publications (1)

Publication Number Publication Date
US20030100610A1 true US20030100610A1 (en) 2003-05-29

Family

ID=11448595

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/281,208 Abandoned US20030100610A1 (en) 2001-11-12 2002-10-28 Use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events
US10/778,182 Active 2024-09-14 US7553870B2 (en) 2001-11-12 2004-02-17 Use of polyunsaturated fatty acid for the primary prevention of major cardiovascular events
US11/984,485 Expired - Fee Related US7619002B2 (en) 2001-11-12 2007-11-19 Use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events
US12/568,997 Expired - Fee Related US8648061B2 (en) 2001-11-12 2009-09-29 Use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events

Family Applications After (3)

Application Number Title Priority Date Filing Date
US10/778,182 Active 2024-09-14 US7553870B2 (en) 2001-11-12 2004-02-17 Use of polyunsaturated fatty acid for the primary prevention of major cardiovascular events
US11/984,485 Expired - Fee Related US7619002B2 (en) 2001-11-12 2007-11-19 Use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events
US12/568,997 Expired - Fee Related US8648061B2 (en) 2001-11-12 2009-09-29 Use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events

Country Status (10)

Country Link
US (4) US20030100610A1 (en)
EP (1) EP1310249B1 (en)
JP (1) JP4731789B2 (en)
AT (1) ATE331510T1 (en)
CY (1) CY1105119T1 (en)
DE (1) DE60212786T2 (en)
DK (1) DK1310249T3 (en)
ES (1) ES2262741T3 (en)
IT (1) ITMI20012384A1 (en)
PT (1) PT1310249E (en)

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070021504A1 (en) * 2005-07-08 2007-01-25 Mochida Pharmaceutical Co., Ltd. Composition and/or method for preventing onset and/or recurrence of cardiovascular events
US20070104779A1 (en) * 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
US20080200547A1 (en) * 1999-01-27 2008-08-21 Malcolm Peet Highly Purified Ethyl EPA and Other EPA Derivatives
US20100278879A1 (en) * 2009-04-29 2010-11-04 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
US20100311834A1 (en) * 2009-02-10 2010-12-09 Amarin Corporation Plc. Methods of treating hypertriglyceridemia
US20110034555A1 (en) * 2009-06-15 2011-02-10 Amarin Pharma , Inc. Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20110218243A1 (en) * 2010-03-04 2011-09-08 Amarin Pharma, Inc. Compositions and methods for treating and/or preventing cardiovascular disease
CN102050720B (en) * 2005-05-04 2013-03-13 普罗诺瓦生物医药挪威公司 Novel DHA derivative and its usage as medicine
US8563608B2 (en) 2009-04-29 2013-10-22 Amarin Pharmaceuticals Ireland Limited Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
AU2014203034B2 (en) * 2009-04-29 2016-09-15 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US9603826B2 (en) 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9827219B2 (en) 2012-01-06 2017-11-28 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2019008101A1 (en) 2017-07-06 2019-01-10 Evonik Technochemie Gmbh Enteric coated solid dosage form comprising omega-3 fatty acid amino acid salts
WO2019034698A1 (en) 2017-08-15 2019-02-21 Evonik Technochemie Gmbh Tablets with high active ingredient content of omega-3 fatty acid amino acid salts
US10314803B2 (en) 2008-09-02 2019-06-11 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10493058B2 (en) 2009-09-23 2019-12-03 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US10537544B2 (en) 2011-11-07 2020-01-21 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10668042B2 (en) 2018-09-24 2020-06-02 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
US10888539B2 (en) 2013-09-04 2021-01-12 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
WO2021023849A1 (en) 2019-08-08 2021-02-11 Evonik Operations Gmbh Down streaming process for the production of polyunsaturated fatty acid salts
WO2021023857A1 (en) 2019-08-08 2021-02-11 Evonik Operations Gmbh Solubility enhancement of poorly soluble actives
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US11141399B2 (en) 2012-12-31 2021-10-12 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US11179362B2 (en) 2012-11-06 2021-11-23 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11547710B2 (en) 2013-03-15 2023-01-10 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712428B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20012384A1 (en) * 2001-11-12 2003-05-12 Quatex Nv USE OF POLYUNSATURATED FATTY ACIDS FOR THE PRIMARY PREVENTION OF MAJOR CARDIOVASCULAR EVENTS
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
CN101213281B (en) * 2005-05-04 2013-03-13 普罗诺瓦生物医药挪威公司 New dha derivatives and their use as medicaments
KR101255650B1 (en) * 2005-05-04 2013-04-16 프로노바 바이오파마 너지 에이에스 New DHA derivatives and their use as medicaments
JP5134916B2 (en) * 2005-07-08 2013-01-30 持田製薬株式会社 Composition for preventing cardiovascular events
US7652068B2 (en) * 2005-12-20 2010-01-26 Cenestra Llc Omega 3 fatty acid formulations
ES2277557B1 (en) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. USE OF DOCOSAHEXAENOIC ACID FOR THE TREATMENT OF OXIDATIVE CELL DAMAGE.
US8399516B2 (en) 2006-11-01 2013-03-19 Pronova Biopharma Norge As Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (PPAR)
EP2102139A2 (en) 2006-11-01 2009-09-23 Pronova Biopharma Norge AS Omega-3 lipid compounds
CN101646426A (en) * 2006-11-03 2010-02-10 普罗诺瓦生物医药挪威公司 Fatty acid alcohols
US20080125490A1 (en) * 2006-11-03 2008-05-29 My Svensson Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
US20080306154A1 (en) * 2006-11-03 2008-12-11 My Svensson Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
DK2323647T3 (en) 2008-08-07 2014-12-08 Prodotti Antibiotici Spa LONG-TERM TREATMENT OF symptomatic heart failure
JPWO2010018856A1 (en) * 2008-08-13 2012-01-26 持田製薬株式会社 Prevention / amelioration or treatment of cannabinoid receptor related diseases
US8586567B2 (en) * 2009-10-29 2013-11-19 Acasti Pharma, Inc. Concentrated therapeutic phospholipid compositions
ITMI20100961A1 (en) * 2010-05-27 2011-11-28 Erredue Spa MIXTURES RICH IN OMEGA-3 FATTY ACIDS, THEIR COMPOSITIONS AND THEIR PREPARATION PROCESS
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
KR20140032380A (en) * 2011-02-07 2014-03-14 모찌다 세이야쿠 가부시끼가이샤 Therapeutic agent for diastolic congestive heart failure
EP2675443A1 (en) 2011-02-16 2013-12-25 Pivotal Therapeutics, Inc. Omega 3 fatty acid diagniostic assay for the dietary management of patients with cardiovascular disease (cvd)
CA2827579A1 (en) 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Omega 3 formulations comprising epa, dha and dpa for treatment of risk factors for cardiovascular disease
US20120302639A1 (en) 2011-02-16 2012-11-29 Pivotal Therapeutics Inc. Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US20140191573A1 (en) * 2011-09-24 2014-07-10 Kool Koncepts Limited Energy management system
CN108524483A (en) 2012-01-06 2018-09-14 翁特拉制药公司 Ω -3 polyunsaturated fatty acids of free acid form are rich in DPA compositions
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
WO2014011895A2 (en) * 2012-07-11 2014-01-16 Thetis Pharmaceuticals Llc High solubility acid salts, intravenous dosage forms, nutrition supplementation and methods of use thereof
WO2015171516A1 (en) 2014-05-05 2015-11-12 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
CN107074884A (en) 2014-06-18 2017-08-18 西蒂斯制药有限责任公司 The mineral amino acid compound of activating agent
CN109562186B (en) 2016-06-03 2022-09-13 西蒂斯制药有限责任公司 Compositions and methods relating to salts of specialized proresolving mediators
WO2021197969A1 (en) * 2020-04-01 2021-10-07 Evonik Operations Gmbh Preparation for use as vasorelaxant
WO2021197971A1 (en) * 2020-04-01 2021-10-07 Evonik Operations Gmbh Preparation for use as antioxidant

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2679997B2 (en) 1986-10-15 1997-11-19 株式会社日立製作所 DC circuit breaker
IT1205043B (en) 1987-05-28 1989-03-10 Innova Di Ridolfi Flora & C S PROCEDURE FOR THE EXTRACTION OF POLYUNSATURATED FATTY ACID ESTERS FROM FISH OILS AND PHARMACEUTICAL AND DIETARY COMPOSITIONS CONTAINING SUCH ESTERS
US4918104A (en) * 1987-06-16 1990-04-17 Weiss Howard S Method and composition for increasing the concentration of omega-3 polyunsaturated fatty acids in poultry and poultry eggs and poultry and eggs resulting therefrom
GB2218984B (en) 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
JPH0225447A (en) 1988-07-13 1990-01-26 Nippon Oil & Fats Co Ltd Production of highly unsaturated fatty acids
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
JP2893866B2 (en) * 1990-05-25 1999-05-24 日本油脂株式会社 Antiarrhythmic drugs
GB9125602D0 (en) 1991-12-02 1992-01-29 Efamol Holdings Method of preventing reocclusion of arteries
CN1082909A (en) 1993-01-03 1994-03-02 潘玉珍 Refining docosahexaenoic acid ethyl compound thrombolytic, anti-dementia drug
JPH06263634A (en) * 1993-03-10 1994-09-20 Sagami Chem Res Center Calcium antagonistic
US5760081A (en) * 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
IT1274734B (en) 1994-08-25 1997-07-24 Prospa Bv PHARMACEUTICAL COMPOSITIONS CONTAINING POLYUNSATURATED FATTY ACIDS, THEIR ESTERS OR SALTS, WITH VITAMINS OR ANTIOXIDANT PROVITAMINS
US5541225A (en) 1994-10-11 1996-07-30 The General Hospital Corporation α-Linolenic acid and eicosatetraynoic acid in the prevention and treatment of ventricular tachyarrhythmia
NL9401743A (en) 1994-10-20 1996-06-03 Prospa Bv Salts of amino alcohols and pharmaceutical formulations containing them.
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
PL186618B1 (en) * 1995-11-28 2004-02-27 Braun Melsungen Ag Lipidic compositions optimised in respect to hydrolysis and their application
IT1277953B1 (en) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti PHARMACEUTICAL COMPOSITION CONTAINING L-CARNITINE OR AN ALCANOYL L-CARNITINE AND A 3-OMEGA SERIES POLYUNSATURED ACID USEFUL
JPH10139664A (en) * 1996-11-12 1998-05-26 Sagami Chem Res Center Antiarrhythmic agent
JPH11239464A (en) * 1997-06-16 1999-09-07 Nippon Suisan Kaisha Ltd Composition having activity to remove risk factor during exercise
CA2313024C (en) 1997-12-10 2008-06-03 Severson, Mary L. Pharmaceutical compositions containing an omega-3 fatty acid oil
DE19855426A1 (en) * 1998-12-02 2000-06-08 Wolfgang Langhoff Agents for the therapy and prophylaxis of rheumatic-arthritic diseases and for the prophylaxis of cardiovascular diseases
IT1308613B1 (en) 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa ESSENTIAL FATTY ACIDS IN THE PREVENTION OF CARDIOVASCULAR EVENTS.
AUPQ480399A0 (en) 1999-12-22 2000-02-03 Commonwealth Scientific And Industrial Research Organisation Unsaturated fatty acids and their uses in therapy
AU3846801A (en) * 2000-02-16 2001-08-27 Brigham & Womens Hospital Aspirin-triggered lipid mediators
ES2246769T3 (en) * 2000-05-22 2006-03-01 Pro Aparts - Investimentos E Consultoria Lda COMPOSITION OF FATTY ACIDS CONTAINING AT LEAST 80% IN WEIGHT OF EPA AND DHA OR ITS DERIVATIVES AND THEIR PHARMACEUTICAL USE.
ITMI20010129A1 (en) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa ESSENTIAL FATTY ACIDS IN THE THERAPY OF HEART INSUFFICIENCY AND HEART FAILURE
JP4337273B2 (en) * 2001-04-20 2009-09-30 日本水産株式会社 Basal metabolism enhancer
EP1279400A1 (en) * 2001-07-25 2003-01-29 Target Hit sa Modifying the fatty acid composition of cell membranes of organs and tissues
AU784852B2 (en) * 2001-08-10 2006-07-06 Mars, Incorporated Canine support diet
ITMI20012384A1 (en) 2001-11-12 2003-05-12 Quatex Nv USE OF POLYUNSATURATED FATTY ACIDS FOR THE PRIMARY PREVENTION OF MAJOR CARDIOVASCULAR EVENTS
EP1450787A4 (en) 2001-11-15 2006-01-25 Galileo Pharmaceuticals Inc Formulations and methods for treatment or amelioration of inflammatory conditions
JP2010510313A (en) 2006-11-22 2010-04-02 リライアント・ファーマシューティカルズ・インコーポレイテッド Prevention and treatment of atrial fibrillation with omega-3 fatty acids

Cited By (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110065793A1 (en) * 1999-01-27 2011-03-17 Amarin Corporation Plc. Highly purified ethyl epa and other epa derivatives
US20080200547A1 (en) * 1999-01-27 2008-08-21 Malcolm Peet Highly Purified Ethyl EPA and Other EPA Derivatives
US8188146B2 (en) 1999-01-27 2012-05-29 Amarin Corporation Plc. Highly purified ethyl EPA and other EPA derivatives
CN102050720B (en) * 2005-05-04 2013-03-13 普罗诺瓦生物医药挪威公司 Novel DHA derivative and its usage as medicine
US8367725B2 (en) * 2005-07-08 2013-02-05 Mochida Pharmaceutical Co., Ltd. Composition and/or method for preventing onset and/or recurrence of cardiovascular events
US20070021504A1 (en) * 2005-07-08 2007-01-25 Mochida Pharmaceutical Co., Ltd. Composition and/or method for preventing onset and/or recurrence of cardiovascular events
US9198892B2 (en) 2005-07-08 2015-12-01 Mochida Pharmaceutical Co., Ltd. Composition and/or method for preventing onset and/or recurrence of cardiovascular events
US20070104779A1 (en) * 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
US10314803B2 (en) 2008-09-02 2019-06-11 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
US8293727B2 (en) 2009-02-10 2012-10-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US8440650B1 (en) 2009-02-10 2013-05-14 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US8293728B2 (en) 2009-02-10 2012-10-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US8524698B2 (en) 2009-02-10 2013-09-03 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US8314086B2 (en) 2009-02-10 2012-11-20 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US8318715B2 (en) 2009-02-10 2012-11-27 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US8324195B2 (en) 2009-02-10 2012-12-04 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US8357677B1 (en) 2009-02-10 2013-01-22 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US8367652B2 (en) 2009-02-10 2013-02-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20100311834A1 (en) * 2009-02-10 2010-12-09 Amarin Corporation Plc. Methods of treating hypertriglyceridemia
US8377920B2 (en) 2009-02-10 2013-02-19 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US8546372B2 (en) 2009-02-10 2013-10-01 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US8399446B2 (en) 2009-02-10 2013-03-19 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US8518929B2 (en) 2009-02-10 2013-08-27 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US8415335B2 (en) 2009-02-10 2013-04-09 Amarin Pharmaceutical Ireland Limited Methods of treating hypertriglyceridemia
US8426399B2 (en) 2009-02-10 2013-04-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US8431560B1 (en) 2009-02-10 2013-04-30 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US10881632B2 (en) 2009-04-29 2021-01-05 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US9855237B2 (en) 2009-04-29 2018-01-02 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
US8445013B2 (en) 2009-04-29 2013-05-21 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US8454994B2 (en) 2009-04-29 2013-06-04 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US11103477B2 (en) 2009-04-29 2021-08-31 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US8501225B2 (en) 2009-04-29 2013-08-06 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US10449172B2 (en) 2009-04-29 2019-10-22 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US8298554B2 (en) 2009-04-29 2012-10-30 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US10265287B2 (en) 2009-04-29 2019-04-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing triglycerides and LDL-C
US8551521B2 (en) 2009-04-29 2013-10-08 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US8563608B2 (en) 2009-04-29 2013-10-22 Amarin Pharmaceuticals Ireland Limited Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US8613945B2 (en) 2009-04-29 2013-12-24 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US8618166B2 (en) 2009-04-29 2013-12-31 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
US8617594B2 (en) 2009-04-29 2013-12-31 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US8617593B2 (en) 2009-04-29 2013-12-31 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US8623406B2 (en) 2009-04-29 2014-01-07 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US8642077B2 (en) 2009-04-29 2014-02-04 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US8663662B2 (en) 2009-04-29 2014-03-04 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
US11147787B2 (en) 2009-04-29 2021-10-19 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US8680144B2 (en) 2009-04-29 2014-03-25 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
US8691871B2 (en) 2009-04-29 2014-04-08 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
US8703185B2 (en) 2009-04-29 2014-04-22 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US10220013B2 (en) 2009-04-29 2019-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
US8709475B2 (en) 2009-04-29 2014-04-29 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US9056088B2 (en) 2009-04-29 2015-06-16 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising fatty acids
US9060983B2 (en) 2009-04-29 2015-06-23 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US9060982B2 (en) 2009-04-29 2015-06-23 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US9072715B2 (en) 2009-04-29 2015-07-07 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
CN104856985A (en) * 2009-04-29 2015-08-26 阿马里纳制药爱尔兰有限公司 Stable pharmaceutical composition and methods of using same
US9138415B2 (en) 2009-04-29 2015-09-22 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US11154526B2 (en) 2009-04-29 2021-10-26 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
US11213504B2 (en) 2009-04-29 2022-01-04 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
AU2014203034B2 (en) * 2009-04-29 2016-09-15 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US8445003B2 (en) 2009-04-29 2013-05-21 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US11033523B2 (en) 2009-04-29 2021-06-15 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
US9585856B2 (en) 2009-04-29 2017-03-07 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US10842766B2 (en) 2009-04-29 2020-11-24 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US10888537B2 (en) 2009-04-29 2021-01-12 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising omega-3 fatty acids
US11690820B2 (en) 2009-04-29 2023-07-04 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
US11400069B2 (en) 2009-04-29 2022-08-02 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
US10010517B2 (en) 2009-04-29 2018-07-03 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US10792267B2 (en) 2009-04-29 2020-10-06 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
US10940131B2 (en) 2009-04-29 2021-03-09 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
RU2723555C2 (en) * 2009-04-29 2020-06-16 Амарин Фарма, Инк. Stable pharmaceutical compositions and methods of using them
US10987331B2 (en) 2009-04-29 2021-04-27 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
US20100278879A1 (en) * 2009-04-29 2010-11-04 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
US10624870B2 (en) 2009-04-29 2020-04-21 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
WO2010127103A1 (en) * 2009-04-29 2010-11-04 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
US8710041B2 (en) 2009-06-15 2014-04-29 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy
US11439618B2 (en) 2009-06-15 2022-09-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides
US11464757B2 (en) 2009-06-15 2022-10-11 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides
US10842768B2 (en) 2009-06-15 2020-11-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides
US8455472B2 (en) 2009-06-15 2013-06-04 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US8410086B2 (en) 2009-06-15 2013-04-02 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides
US8669245B2 (en) 2009-06-15 2014-03-11 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US20110034555A1 (en) * 2009-06-15 2011-02-10 Amarin Pharma , Inc. Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US11007173B2 (en) 2009-09-23 2021-05-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US10493058B2 (en) 2009-09-23 2019-12-03 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US20110218243A1 (en) * 2010-03-04 2011-09-08 Amarin Pharma, Inc. Compositions and methods for treating and/or preventing cardiovascular disease
US11712428B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US10537544B2 (en) 2011-11-07 2020-01-21 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US10632094B2 (en) 2011-11-07 2020-04-28 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US9827219B2 (en) 2012-01-06 2017-11-28 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject
US10973796B2 (en) 2012-01-06 2021-04-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity C-reactive protein (hs-CRP) in a subject
US10576054B1 (en) 2012-06-29 2020-03-03 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
US10278936B2 (en) 2012-06-29 2019-05-07 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10016386B2 (en) 2012-06-29 2018-07-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10278935B2 (en) 2012-06-29 2019-05-07 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9918955B2 (en) 2012-06-29 2018-03-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10278939B2 (en) 2012-06-29 2019-05-07 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9603826B2 (en) 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9918954B2 (en) 2012-06-29 2018-03-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10555924B2 (en) 2012-06-29 2020-02-11 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
US9610272B2 (en) 2012-06-29 2017-04-04 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10568861B1 (en) 2012-06-29 2020-02-25 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
US10278938B2 (en) 2012-06-29 2019-05-07 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10383840B2 (en) 2012-06-29 2019-08-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
US10278937B2 (en) 2012-06-29 2019-05-07 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10555925B1 (en) 2012-06-29 2020-02-11 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
US9623001B2 (en) 2012-06-29 2017-04-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10792270B2 (en) 2012-06-29 2020-10-06 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
US9693985B2 (en) 2012-06-29 2017-07-04 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9693986B2 (en) 2012-06-29 2017-07-04 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US10894028B2 (en) 2012-06-29 2021-01-19 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
US9693984B2 (en) 2012-06-29 2017-07-04 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US11229618B2 (en) 2012-11-06 2022-01-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US11179362B2 (en) 2012-11-06 2021-11-23 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US11141399B2 (en) 2012-12-31 2021-10-12 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US10973797B2 (en) 2013-02-06 2021-04-13 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein c-III
US10265290B2 (en) 2013-02-06 2019-04-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US11185525B2 (en) 2013-02-06 2021-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US10610508B2 (en) 2013-02-06 2020-04-07 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US10166209B2 (en) 2013-02-06 2019-01-01 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US10675263B2 (en) 2013-02-06 2020-06-09 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US10167467B2 (en) 2013-02-13 2019-01-01 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US10851374B2 (en) 2013-02-13 2020-12-01 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9855240B2 (en) 2013-02-19 2018-01-02 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US10206898B2 (en) 2013-03-14 2019-02-19 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US11547710B2 (en) 2013-03-15 2023-01-10 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US10888539B2 (en) 2013-09-04 2021-01-12 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US10292959B2 (en) 2013-10-10 2019-05-21 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10722485B2 (en) 2013-10-10 2020-07-28 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US11285127B2 (en) 2013-10-10 2022-03-29 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US11052063B2 (en) 2014-06-11 2021-07-06 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US11446269B2 (en) 2014-06-16 2022-09-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10842765B2 (en) 2016-03-15 2020-11-24 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
WO2019008101A1 (en) 2017-07-06 2019-01-10 Evonik Technochemie Gmbh Enteric coated solid dosage form comprising omega-3 fatty acid amino acid salts
WO2019034698A1 (en) 2017-08-15 2019-02-21 Evonik Technochemie Gmbh Tablets with high active ingredient content of omega-3 fatty acid amino acid salts
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US11369582B2 (en) 2018-09-24 2022-06-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
US11298333B1 (en) 2018-09-24 2022-04-12 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
US10668042B2 (en) 2018-09-24 2020-06-02 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
US11116742B2 (en) 2018-09-24 2021-09-14 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
US10786478B2 (en) 2018-09-24 2020-09-29 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
US11116743B2 (en) 2018-09-24 2021-09-14 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
US11000499B2 (en) 2018-09-24 2021-05-11 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
US11717504B2 (en) 2018-09-24 2023-08-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
WO2021023857A1 (en) 2019-08-08 2021-02-11 Evonik Operations Gmbh Solubility enhancement of poorly soluble actives
WO2021023849A1 (en) 2019-08-08 2021-02-11 Evonik Operations Gmbh Down streaming process for the production of polyunsaturated fatty acid salts

Also Published As

Publication number Publication date
CY1105119T1 (en) 2009-11-04
ITMI20012384A1 (en) 2003-05-12
ATE331510T1 (en) 2006-07-15
US8648061B2 (en) 2014-02-11
US20080269331A1 (en) 2008-10-30
JP2003146874A (en) 2003-05-21
ES2262741T3 (en) 2006-12-01
US7553870B2 (en) 2009-06-30
US20100016428A1 (en) 2010-01-21
US20040162349A1 (en) 2004-08-19
EP1310249B1 (en) 2006-06-28
DE60212786T2 (en) 2007-06-28
DE60212786D1 (en) 2006-08-10
JP4731789B2 (en) 2011-07-27
EP1310249A1 (en) 2003-05-14
DK1310249T3 (en) 2006-09-25
US7619002B2 (en) 2009-11-17
PT1310249E (en) 2006-09-29

Similar Documents

Publication Publication Date Title
US8648061B2 (en) Use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events
Billman et al. Prevention of ischemia-induced cardiac sudden death by n− 3 polyunsaturated fatty acids in dogs
EP1474125A1 (en) The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure
US20060135607A1 (en) Drug for improving prognosis for subarachnoid hemorrhage
NO328797B1 (en) Use of essential fatty acids containing a mixture of eicosapentaenoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA) for the preparation of a drug useful in preventing death in a patient who has had a heart attack.
US20140322314A1 (en) Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment
US9393224B2 (en) Prophylactic and/or therapeutic agent for cardiovascular complications of diabetes
EP0282696B1 (en) Use of pyridoxine derivatives in the prophylaxis and treatment of hyperlipemia and atherosclerosis
WO2008066745A9 (en) Prophlyaxis and treatment of atrial fibrillation with omega-3 fatty acids
US20130236551A1 (en) Combination composition useful for treating cardiovascular diseases
US8592439B2 (en) Long-term treatment of symptomatic heart failure
US20050245610A1 (en) Essential fatty acids in the treatment and/or inhibition of depression in patients with coronary heart or artery disease
JPH0429928A (en) Antiarrhythmic agent
AU2005244483B2 (en) Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease
JP2007532605A5 (en)
Szekeres et al. The Effect of Non-steroidal Anti-inflammatory Drugs and of a Linoleic Acid-rich Diet on Early Arrhythmias Resulting from Myocardial Ischaemia
DE10006836A1 (en) Therapeutic treatment of bed-wetting using polyunsaturated fatty acids, e.g. eicosapentaenoic acid, administered as capsules containing fish oil concentrate
DE10019052A1 (en) Use of polyunsaturated fatty acids for the treatment of enuresis and incontinence

Legal Events

Date Code Title Description
AS Assignment

Owner name: QUATEX N.V., NETHERLANDS ANTILLES

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HAJIME, SHIBUYA;REEL/FRAME:014193/0725

Effective date: 20020925

AS Assignment

Owner name: QUATEX N.V., NETHERLANDS ANTILLES

Free format text: RECORD TO CORRECT ASSIGNOR'S NAME ON AN ASSIGNMENT PREVIOUSLY RECORDED AT REEL 014193 FRAME 0725;ASSIGNOR:SHIBUYA, HAJIME;REEL/FRAME:015031/0965

Effective date: 20020925

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: PRO APARTS INVESTIMENTOS E CONSULTORIA LDA., PORTU

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:QUATEX N.V.;REEL/FRAME:015203/0939

Effective date: 20040624